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Role of Pharmacist During the COVID‐19 
Pandemic
In December 2019, a respiratory illness due to a novel coronavirus, SARS‐
CoV‐2, was first identified in China. The respiratory illness due to SARS‐
CoV‐2, termed COVID‐19, is now a worldwide pandemic and has been 
identified in more than 200 countries and almost one million people. 
Common symptoms of COVID‐19 include cough, shortness of breath, and 
fever; disease ranges in severity from asymptomatic infection, mild disease 
(in 81% of patients), to pneumonia, respiratory failure, and death. 
The inability to test widely and quickly has hindered the ability to 
characterize the epidemiology of the disease, prevent further spread, and 
ensure the optimal use of other limited resources such as personal protective 
equipment (PPE) and medication therapy. Pharmacists play an essential and 
unique role within the healthcare team to optimize patient care during this 
COVID‐19 pandemic.
Antiviral stewardship is vital during the pandemic. In lieu of antivirals 
with established efficacy for COVID‐19, novel experimental agents are 
currently being evaluated in controlled studies globally for the prophylaxis 
and treatment of COVID‐19. Naturally, pharmacists are essential in 
facilitating investigational drug studies in health systems but they are also 
integral to helping obtain medication through compassionate use protocols. 
While investigational drug pharmacists play a significant role here, 
active involvement of those practicing in infectious diseases, information 
technology, critical care, distribution, and management can streamline the 
process and speed the time to therapy for study patients.
While no agents are currently FDA‐approved for treatment of COVID‐19, 
a number of drugs approved for other indications are of great interest 
for repurposing for COVID‐19 treatment,  such as lopinavir/ritonavir, 
chloroquine, and hydroxychloroquine; or may be immune‐modulating 
agents, such as tocilizumab or interferons. If these agents are used, it is the 
pharmacist’s role to provide accurate data to the providers about safe drug 
delivery (eg, how to formulate oral drugs when patients cannot swallow), 
drug‐drug interactions, and adverse effects. Patients also need appropriate 
counseling about their use and potential harms, especially if use in the 
community becomes widespread.
One of the fundamental role of pharmacist is to ensure the availability 
and timely provision of the safest and most effective therapy. In this role, 
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pharmacists must plan for, identify and mitigate drug shortages during the COVID‐19 pandemic. This is 
crucial given that drug shortages can lead to prescribing of suboptimal therapy and have been associated with 
patient harm. When there are limited suppliers of raw materials or active pharmaceutical ingredients (API), 
drug shortages easily occur. Therefore, pharmacists must work pro-actively to identify effective therapeutic 
alternatives, enforce the implementation of drug shortage mitigation strategies, and if needed, prioritize drug 
supply to the patients who are most likely to benefit. Examples of safe usage, formulary restriction for COVID‐19 
therapies that are in limited supply (ie, hydroxychloroquine) have educated providers about the restrictions, and 
have implemented electronic alerts to prescribers upon ordering. 
Pharmacists can take steps to minimize unnecessary PPE use by helping limit unnecessary entry into the patient 
room. This can be done by aligning medication administration times, IV to PO switching when possible to 
decrease nurses needing to respond to pump alerts, and ensuring lab draws, including therapeutic drug monitoring 
are necessary and if possible are timed with other patient interactions. We can also limit staff to aerosolized 
exposure of the virus by developing treatment protocols that limit unnecessary nebulizer use and instead favor 
use of metered dose inhalers for inpatients. Furthermore, medication teaching of patients who are COVID‐19‐
positive or persons under investigation for COVID‐19 can be facilitated by telehealth approaches to minimize 
exposure to pharmacists.
Lastly, pharmacists are a trusted and accessible resource for the public during this public health emergency, 
especially community pharmacists. Pharmacists must educate their patients and the public on effective strategies 
to prevent acquisition and further spread of infection (eg, optimal hand hygiene, social distancing, staying home 
if having respiratory symptoms), symptomatic relief, and the best resources for current COVID‐19 information. 
In conclusion, the genesis of the COVID‐19 pandemic occurred less than 4 months ago, our knowledge about 
the disease is changing daily, and it is uncertain how long the pandemic will last. Pharmacists play a key role as 
the drug information expert in evaluating literature related to new or repurposed therapies and can help make 
system‐level and patient‐specific treatment decisions, as well as ensure access to these therapies and other drugs 
on shortage due the pandemic. 
References:
•	 National Institutes of Health U.S. National Library of Medicine. Adaptive COVID‐19 Treatment Trial
•	 Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020.
•	 accpjournals.onlinelibrary
ASK AWAY 
You may get an experts opinion by consulting with one of our specialist. Send in your questions at drug.information@aku.edu 
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Stewardship of Off-Label Treatments for COVID-19| An Evidence 
Based Practice
The COVID-19 pandemic has become a public health emergency. While researchers are working to find a 
treatment for the infection, no medication is currently approved by any international regulators like USFDA to 
treat COVID-19. Some already approved medications for other indications are being tried as off-label treatments 
of COVID-19.
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The Pharmacy & Therapeutics Committee (P&TC) in line with current international literature suggested some 
recommendations as a general guide for prescribers and pharmacists when considering the appropriate use of 
experimental treatments. These especially include Azithromycin, Chloroquine, and Hydroxychloroquine, and 
oseltamivir.
Recommendation 1: Any prescription or medication order for a drug that is also being investigated for 
the off-label treatment of COVID-19 should be reviewed for appropriateness.
1. Patients who are already prescribed these medications for non-COVID-19 indications should continue to 
	 have	access	through	new	prescriptions	or	refills	of	existing	prescriptions.
 
2. Outpatient prescriptions for these medications should include a documented diagnosis from the prescriber 
 with the FDA-approved indication or other literature-supported, off-label use.
3.   Pharmacists should verify new prescriptions for these medications are appropriate, recognizing that patients 
newly diagnosed with conditions like rheumatoid arthritis or lupus may be initiating treatment during the 
coming weeks or months.
Recommendation 2: Prescriptions or medication orders for the off-label treatment of confirmed COVID-19 
patients should be prioritized for inpatient use and limited in duration of treatment.
1.	 Decisions	 to	 use	 off-label	 medications	 to	 treat	 confirmed	 COVID-19	 patients	 should	 be	 made	 by	 the	
interprofessional	team	after	weighing	supporting	evidence,	risks,	and	potential	benefits.	
2.	 Informed	 consent	 describing	 the	 existing	 evidence,	 risks,	 and	 potential	 benefits	 should	 be	 established	
between providers and patients, caregivers.
3. If patients initiated on treatment during inpatient admission must continue treatment upon discharge, 
prescriptions should be coordinated through direct communication with an outpatient pharmacy. 
4. Outpatient prescriptions should be dispensed only: 
a. In coordination with discharge planning from an inpatient setting for continuity of care, or 
b.	 For	patients	with	a	confirmed	positive	test	for	SARS-CoV-2.
c. Outpatient prescriptions should be limited to no more than a fourteen-day supply.
d.	 Refills	should	not	be	permitted.
Recommendation 3: Inventory of drugs being studied for the treatment of COVID-19 should be maintained 
responsibly.
1. Pharmacies, especially outpatient pharmacies, should not attempt to buy up and hoard inventories that 
 will be most appropriately used in inpatient settings.
2. These medications should be stored with limited access. 
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Hafsah Ashfaq, Clinical Pharmacist
Hydroxychloroquine (HCQ) and Chloroquine are the antimalarial agents and has a new emerging role in 
treatment of COVID-19 Pneumonia (Off-label). There is a French study showing the combination of HCQ 
and azithromycin to prevent bacterial Super infections. Despite its small sample size the survey shows that 
hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 
patients and its effect is reinforced by azithromycin. Both these drugs are associated with significant adverse 
effects, hepatotxicity and risk of sudden death, especially when used with Azithromycin may enhance the overall 
QTc prolongation. So it is recommended  use with caution and monitoring. Additionally, elderly patients with 
other serious underlying diseases, who are already vulnerable to complications from COVID-19 infection, may 
be at higher risk for cardiac and hepatic side effects from these agents.
 
For details visit ;
Gautret	et	al.	(2020)	Hydroxychloroquine	and	azithromycin	as	a	treatment	of		COVID‐19: results of an open‐label non‐
randomized clinical trial. International Journal of  Antimicrobial Agents – In Press 17 March 2020 – DOI : 10.1016/j.ijantimicag.2020.105949 
Call at Drug & Poison Information Center.
A Physician from a local Hospital called at Drug & Poison Information Centre ( DPIC) – AKUH for the 
management of a poisoning case where a child chewed household bleach containing polythene bag.
According to her the Patient was vitally stable but unable to talk and open 
his mouth because of swelling on lips and mouth. They have given  single 
dose of Inj. Pheniramine and Inj. Hydrocortisone. But not observed much 
improvement. Our DPIC Pharmacist, advice physician to dilute with small 
amounts of milk or water. Activated charcoal is CONTRAINDICATED. 
Local  application of anesthehic agent ( Lidocaine 2%) on the lips and 
around the mouth with a cotton is advised and continue with the injections of antihistamine, Pheniramine. 
Followup :
Our DPIC Pharmacist as a regular practice has taken the followup. As per the Physician, the patient symptoms 
remarkably reduced and swelling returned to normal. 
ToxTalk | Bleach Ingestion
Faqeeha Shakeel, Pharmacist 
Household poisons are substances in your home that can cause harm when swallowed, ingested, inhaled 
or touched. They include cleaning products, detergents, medicines and other common household products. 
Poisoning occurs most often in toddlers when children are exploring things at home. It’s usually common in 
children less than 5 years of age. 
In Pakistan, there are hoards of chemicals and cleaning agents available in the market in polythene bags and 
unlabelled containers that leads to the poisoning of such chemicals in the children. Most household bleach 
solutions contain 3% to 5% hypochlorite. Below mentioned is one of the case that Drug & Poison Information 
Centre (DPIC) Pharmacist dealt with.
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COVID-19- Recommended Practices.
The virus appears to require close contact for human-to-human 
transmission (i.e., within 6 feet) and primarily spreads via 
droplets released when someone sneezes or coughs.
Take steps to protect yourself
Clean your hands often
 Wash your hands with soap and water for at least 20 seconds   
 frequently especially after you have been in a public place, or  
 after blowing your nose, coughing, or sneezing.
 If soap and water are not readily available, use a hand sanitizer  
 that contains at least 60% alcohol. Cover all surfaces of your   
 hands and rub them together until  they feel dry.
 Cough or Sneeze into your Sleeve.
 Avoid touching your eyes, nose, and mouth with unwashed hands.
 Immediately discard used tissues.
Practice social distancing, 
 Walk apart from one another.
 Avoid close contact with people who are sick. 
 Avoid hand shake.
 Be aware of where you place your hands and body.
Tips to Prevent Household Poisoning- Keep Child Safe.
•	 Store chemicals and cleaners out of sight and reach of children at all times.
•	 Don’t keep the chemicals into used juice or soft drink bottles.
•	 Put all chemicals and cleaners away 
immediately after finishing the use. 
•	 Safe disposal of chemicals when used is 
necessary.
•	 Never put cocroach powders or rat poison 
on the floors of your home. Do not use 
insect sprays on furniture or mattresses.
•	 Keep laundry and dishwasher supplies out 




If you think your child has swallowed something poisonous, call the Drug & Poisons Information 
Centre on 021-34861504/1506 immediately.
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Drug Induced Nutrient & Vitamin Deficiency 
Bilal Ahmad- Pharmacist
 
Introduction: Therapy optimization and reducing drug related harms is a critical and in-depth process to improve 
patient safety and health quality. The pharmacist reviews the medication order for appropriateness to rule out 
and minimize drug-drug and drug-food interactions, which lead to nutrients depletion-vital for physiological 
functions. Drug utilization review is an optimal approach in community setting to identify address and intervene 
the issue. The topic will highlight the major contributing medications lead to deficiency.
Recommendations for pharmacists: 
o	 Pharmacist is required to review the order and identify the risk factors for nutrient depletion.
o	 Underlying deficiency need to be evaluated for primary reasons.
o	 To minimize the drug-food interaction, suggest gap between food and dose to be taken.
o	 To evaluate the need for replacement, or can be overcome by diet.
o	 Serum levels should be suggested before therapeutic replacement.
o	 Counsel the patient, about the ways to minimize risk factors.
Nutrient Formulary Supplements
Calcium Syrup. Calcium carbonate
Qalsan-D, Chewcal, CAC1000 & Boncal plus.
Coenzyme Q10 Tab 30mg
Folic Acid Tab. Folic Acid 5mg
Magnesium Syp. Magnesium Chloride
Inj. Magnesium Sulphate
Vitamin B6 Tab. Vita-6 50mg
Thiamine Tab & Inj. Neurobion ( Vit B1, B6 and B12)
Potassium Tab. Neo-K 500mg (6.7mEq)   Syp. Potassium chloride 
13.33mEq/5ml     Inj. Potassium chloride (1mEq/ml)
Vitamin A Cap. 10,000, 100,000 and 200,000 units
Syp. 5000/5ml, Drops. 2666IU/drop   Tab. 2500 IU
Vitamin B12 Methycobal® Tab & Inj 500 mcg
Vitamin K Tab & inj 10mg
Vitamin D Capsules (50k & 2lac, tablets (2000IU), Drops 400IU 
and Injection (2 &6 lac).
Zinc Syp 20mg/5ml 110 & 220mg Cap (compounded)
Common Drug-Nutrient Depletions
The Aga Khan University Hospital, Karachi
Provide us your Valuable Feedback!
To keep the Pharmacy Newsletter of Aga Khan University Hospital (AKUH) updated we would like to take your valuable feedback. We are grateful 
to you for sparing few minutes of your precious time to complete form by below online link or form can be emailed to you as well. Just drop us an 
email with subject Newsletter Feedback. Email us at:drug.information@aku.edu 
For Formulary supplements assistance visit  http://portal.aku.edu/pharmacy/olf.asp or Call 1504/1506
Thank you in advance for your feedback! Link: https://forms.gle/FCo9ZuE4CConzFp46
